首页> 外文期刊>BMC Cardiovascular Disorders >Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up
【24h】

Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up

机译:患者在日常做法中与维生素K拮抗剂口腔抗凝的自我管理:长期随访后单个中心队列中的临床结果

获取原文
           

摘要

Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very promising model of care for oral anticoagulation in terms of efficacy and safety. In comparison with other management models of VKA therapy, the number of scientific publications supporting the advantages of PSM is more limited. Currently, most of the scarce information comes from randomized clinical trials. Moreover, a small number of studies have assessed PSM of VKA therapy in real life conditions. We analyzed clinical outcomes of 927 patients in a single center (6018.6 patient-years of follow-up). Recruitment took place between 2002 and 2017. All patients followed a structured training program, conducted by specialized nurses. Fifty percent of individuals had a mechanical heart valve (MHV), 23% suffered from recurrent venous thromboembolism (VTE) or high-risk thrombophilia, and 13% received VKA therapy because of atrial fibrillation (AF). Median follow-up was 6.5?years (range 0.1–15.97?years), median age was 58.1?years (IQR 48–65.9) and 46.5% were women. The incidence of major complications (either hemorrhagic or thromboembolic) was 1.87% patient-years (pt-ys) with a 95% CI of 1.54–2.27. The incidence of major thromboembolic events was 0.86% pt-ys (95% CI 0.64–1.13) and that of major hemorrhagic events was 1.01% pt-ys (95% CI 0.77–1.31). The incidence of intracranial bleeding was 0.22% pt-ys (95% CI 0.12–0.38). In terms of clinical indication for VKA therapy, the incidence of total major complications was 2.4% pt-ys, 2.0% pt-ys, 0.9% pt-ys and 1.34% pt-ys for MHV, AF, VTE and other (including valvulopathies and myocardiopathies), respectively. Clinical outcomes were worse in patients with multiple comorbidities, previous major complications during conventional VKA therapy, and in older individuals. The percentage of time in therapeutic range (TTR) was available in 861 (93%) patients. Overall, the mean (SD) of TTR was 63.6?±?13.4%, being higher in men (66.2?±?13.1%) than women (60.6?±?13.2%), p??0.05. In terms of clinically relevant outcomes (incidence of major complications and mortality), PSM in real life setting seems to be a very good alternative in properly trained patients.
机译:维生素K拮抗剂(VKA)的患者自我管理(PSM)似乎是在疗效和安全性方面对口服抗凝的非常有前途的护理模型。与VKA治疗的其他管理模型相比,支持PSM优势的科学出版物的数量更有限。目前,大多数稀缺信息来自随机临床试验。此外,少数研究在现实生活条件下评估了VKA治疗的PSM。我们在单一中心分析了927名患者的临床结果(6018.6患者的随访)。招聘发生在2002年至2017年之间。所有患者遵循由专业护士进行的结构化培训计划。 50%的个体具有机械心脏瓣膜(MHV),23%患有复发性静脉血栓栓塞(VTE)或高风险血栓性血栓性血栓性,并且由于心房颤动(AF),13%接受了VKA治疗。中位后续时间为6.5?年(范围0.1-15.97?年),中位年龄为58.1?年(IQR 48-65.9)和46.5%是女性。主要并发症(出血或血栓栓塞)的发生率为1.87%患者 - 年(PT-ys),95%CI为1.54-2.27。主要血栓栓塞事件的发生率为0.86%PT-Ys(95%CI 0.64-1.13),主要出血事件的PT-YS(95%CI 0.77-1.31)。颅内出血的发生率为0.22%Pt-Ys(95%CI 0.12-0.38)。就VKA疗法的临床指示而言,总重复症的发病率为2.4%Pt-ys,2.0%Pt-ys,0.9%Pt-ys,0.9%Pt-ys和MHV,AF,VTE等的1.34%PT-Ys(包括valvulopathies和心肌病分别)分别。多种可用性患者的临床结果更差,常规VKA治疗期间和老年人在常规的主要并发症中。治疗范围(TTR)的时间百分比可在861(93%)患者中。总体而言,TTR的平均值(SD)为63.6?±13.4%,男性更高(66.2?±13.1%)比女性(60.6?±13.2%),p?<0.05。就临床相关结果(主要并发症和死亡率的发生率),在现实生活中的PSM似乎是培训患者的妥善替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号